Bioprocess Simulation and Economics

  • Demetri PetridesEmail author
  • Doug Carmichael
  • Charles Siletti
  • Alexandros Koulouris
Part of the Learning Materials in Biosciences book series (LMB)


This chapter teaches students and practicing engineers the fundamentals of bioprocess simulation, with an emphasis on economic evaluation of integrated biotech processes. Given a product and a desired annual production rate (process throughput), bioprocess simulation endeavors to answer the following and other related questions: What are the required amounts of raw materials and utilities needed for a single batch? What are the required sizes of process equipment and supporting utilities? What is the total capital investment? What is the manufacturing cost? What is the minimum time between consecutive batches? Which process steps or resources are the likely production bottlenecks? What changes can increase throughput and/or reduce costs? What is the environmental impact of the process? Which design is the “best” (fastest or least expensive) among several plausible alternatives?


Computer-aided bioprocess design Bioprocess cost analysis Bioprocess economic evaluation Bioprocess simulation Bioprocess modeling 


  1. 1.
    Douglas JM. Conceptual design of chemical processes. New York: McGraw-Hill; 1988.Google Scholar
  2. 2.
    Frohlich BT. Considerations for developing in-house capabilities for cost of goods estimation. In: Biopharmaceutical process economics and optimization (conference proceedings). Westborough MA; September 30–October 1, 1999.Google Scholar
  3. 3.
    Burk C. Techno-economic modeling for new technology development, Chemical Engineering Progress (CEP), January 2018, pp. 43–52.Google Scholar
  4. 4.
    Korovessi E, Linningerr A. Batch processes. Boca Raton: Taylor & Francis; 2006.Google Scholar
  5. 5.
    Heinzle E, Biwer A, Cooney C. Development of sustainable bioprocesses. West Sussex: Wiley; 2006.CrossRefGoogle Scholar
  6. 6.
    Petrides DP, Koulouris A, Lagonikos PT. The role of process simulation in pharmaceutical process development and product commercialization. Pharm Eng. 2002;22(1):1–8.Google Scholar
  7. 7.
    Toumi A, Jurgens C, Junco C, Maier B, Papavasileiou V, Petrides DP. Design and optimization of a large scale biopharmaceutical facility using process simulation and scheduling tools. Pharm Eng. 2010;20(2):1–9.Google Scholar
  8. 8.
    DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Peters MS, Timmerhaus KD. Plant design and economics for chemical engineers. 4th ed. New York: McGraw-Hill; 1991.Google Scholar
  10. 10.
    Ulrich GD. A guide to chemical process design and economics. New York: Wiley; 1984.Google Scholar
  11. 11.
    Valle-Riestra JF. Project evaluation in the chemical process industries. New York: McGraw-Hill; 1983.Google Scholar
  12. 12.
    Garrett DE. Chemical engineering economics. New York: Van Nostrand Reinhold; 1989.CrossRefGoogle Scholar
  13. 13.
    Seider WD, Seader JD, Lewin DR. Process design principles - synthesis, analysis, and evaluation. New York: Wiley; 1999.Google Scholar
  14. 14.
    Towler G, Sinnott R. Chemical engineering design; principles, practice and economics of plant and process design. London: Butterworth-Heinemann (Elsevier); 2008.Google Scholar
  15. 15.
    Jagschies G. Where is biopharmaceutical manufacturing heading? BioPharm Int. 2008;21(10):72–82.Google Scholar
  16. 16.
    Pollak P, Badrot A, Dach R. API manufacturing: facts and fiction, contract pharma, January/February 2012, issue: 62–63.Google Scholar
  17. 17.
    Pais-Chanfrau J, et al. The impact of disposables on project economics in a new antibody plant: a case study. BioPharm Int. 2009;22(12):62–74.Google Scholar
  18. 18.
    Minow B, Rogge P, Thompson K. Implementing a fully disposable mAb manufacturing facility. BioProcess Int. 2012;10(6):48–57.Google Scholar
  19. 19.
    Papavasileiou V, Siletti C, Petrides D. Systematic evaluation of single-use systems using process simulation tools. The BioPharm International Guide, November 2008. issue: 16–29.Google Scholar
  20. 20.
    Levine HL, Lilia J, Stock R, Gaasvik A, Hummel H, Ransohoff TC, Jones SD. Single-use technology and modular construction. BioProcess Int. 2013;11(4):40–5.CrossRefGoogle Scholar
  21. 21.
    Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7(1):9–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Kelley B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol Prog. 2007;23:995–1008.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Demetri Petrides
    • 1
    Email author
  • Doug Carmichael
    • 1
  • Charles Siletti
    • 1
  • Alexandros Koulouris
    • 2
  1. 1.Intelligen Inc.Scotch PlainsUSA
  2. 2.Alexander Technological Education InstituteThessalonikiGreece

Personalised recommendations